The Federal Trade Commission has once again cautioned companies to make sure that they are within federal guidelines when it comes to selling CBD. On Tuesday, the agency announced that it had issued warning letters to companies that it says were advertising health claims for CBD products “without competent and reliable scientific evidence to support such claims.”
In a statement, the FTC said that letters had been sent to three companies, which it did not publicly identify. It did, however, go into some detail regarding the health claims that each had made for its products. Those specifics are worth studying, especially for other CBD vendors hoping to avoid federal censure.
Company number one had language on its website saying that CBD “works like magic” against “even the most agonizing pain.” It also claims that CBD has been “clinically proven” to treat diseases like cancer and multiple sclerosis, and made reference to “thousands of hours of research” the firm has participated in, in conjuncture with Harvard University.
Company two also called on CBD’s curative effects on a large spectrum of health conditions from Alzheimer’s to Lou Gehrig’s Disease and AIDS. The FTC also flagged the company’s claim that CBD is a